Vol 75, No 1 (2017)
Original articles
Published online: 2016-07-08

open access

Page views 1614
Article views/downloads 2119
Get Citation

Connect on Social Media

Connect on Social Media

Bioequivalence study of 2.5 mg film-coated bisoprolol tablets in healthy volunteers

Katarzyna Buś-Kwaśnik, Piotr J. Rudzki, Hanna Ksycińska, Andrzej Leś, Krystyna Serafin-Byczak, Jerzy Raszek, Agnieszka Bielak, Andrzej Wybraniec, Anna E. Płatek, Filip M. Szymański, Tomasz Łazowski
Kardiol Pol 2017;75(1):48-54.

Abstract

Background: Bisoprolol is one of the most widely used beta-blockers characterised by cardioselectivity, and it has no intrinsic sympathomimetic activity. It is commonly used in the treatment of coronary heart disease and heart failure.  

Aim: The aim of study was to assess the bioequivalence of the film-coated tablets containing 2.5 mg of bisoprolol (Bisocard® — the medicinal product) to the original medicinal product (Concor Cor 2.5® — the reference).  

Methods: A randomised, open-label, two-period, crossover, single-dose, relative bioavailability study was conducted in fasted healthy Caucasian volunteers. A single 10-mg oral dose (four tablets of 2.5 mg) of the test or reference product was followed by a 14-day wash-out period, after which the subjects received the alternative product. Blood was sampled within a period of 60 h post administration in pre-specified time points. Bisoprolol concentrations were determined by a validated LC-MS/MS method. The products were considered bioequivalent if the 90% confidence interval (CI) of the log-transformed geometric mean ratios (test vs. reference) for AUC(0–t), AUC(0–), and Cmax were within 80–125% limits. Adverse events were monitored during the study based on the subject claims and clinical parameters.  

Results: Twenty-six healthy male and female volunteers (mean age ca. 29 years; body mass index 22.7 kg/m2) were in­cluded in the study, and 24 completed the clinical part. The geometric mean ratios (test/reference) for the log-transformed AUC(0–t), AUC(0–), and Cmax were 95.16% (90% CI 92.52–97.87%), 95.08% (90% CI 92.40–97.83%), and 100.00% (90% CI 94.83–105.45%), respectively. There were no significant differences in the pharmacokinetic parameters between the test and reference formulations. No serious adverse events were reported.  

Conclusions: The results of this single-dose study in healthy Caucasian volunteers indicate that Bisocard®; 2.5 mg film-coated tablets are bioequivalent to the reference product — Concor Cor 2.5®; 2.5 mg film-coated tablets. Both products had similar safety profile and have been well tolerated.   

Article available in PDF format

View PDF Download PDF file



Polish Heart Journal (Kardiologia Polska)